Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Nephrology · Fanconi Renotubular Syndrome Type 2

Treatment and Long-Term Management

At a Glance

Fanconi renotubular syndrome type 2 is managed with carefully prescribed phosphate to correct mineral loss, support bone growth, and lower high urine calcium. Regular blood tests and kidney ultrasounds help balance treatment benefits with risks such as high blood calcium and kidney deposits.

Managing Fanconi Renotubular Syndrome Type 2 (FRTS2) focuses on replacing the minerals the kidneys are losing. Because the condition is caused by a specific loss of phosphate, the treatment is designed to replace that phosphate, which improves mineral balance and reduces the harmful spikes in active Vitamin D and calcium [1][2].

The Primary Treatment: Oral Phosphate

The cornerstone of care for FRTS2 is oral phosphate supplementation. By providing extra phosphate by mouth, doctors can restore the body’s mineral balance [1].

  • Dosing: Phosphate dosing is complex. In one small study of 11 children, doctors used doses ranging from 5 to 20 mg/kg/day of elemental phosphorus [2]. This is not a universal protocol; dosages vary heavily based on formulation, age, and individual lab results. Never adjust the dose yourself, as errors in calculating elemental phosphorus versus phosphate salts can lead to severe overdosing.
  • Goals of Treatment: The main goal is to normalize the level of calcium in the urine (hypercalciuria) and promote healthy bone growth [2]. In the small 11-patient study, this treatment helped 10 children achieve normal urine calcium levels and improved growth in nearly all of them [2].
  • Monitoring: Your medical team will regularly check serum phosphate, calcium, and PTH (parathyroid hormone) to ensure the dose is effective without being excessive [3][2].

Vitamin D: Nutritional vs. Active

It is vital to understand the difference between standard nutritional Vitamin D and the “active” form (calcitriol). In FRTS2, the phosphate leak causes the body to produce too much active Vitamin D on its own [4].

Taking additional active Vitamin D (calcitriol) is generally avoided because it can severely worsen high calcium levels in the blood and urine, increasing the risk of kidney stones and calcium deposits (nephrocalcinosis) [5][2]. Standard nutritional Vitamin D may sometimes be prescribed if blood tests reveal a genuine deficiency, but any Vitamin D or calcium supplement must be strictly directed by your specialist based on current lab results [6].

Managing Severe Hypercalcemia

When calcium levels in the blood become dangerously high (severe infantile hypercalcemia), it is a medical emergency that requires hospital assessment and treatment.

  • Hydration: The first step in a hospital setting is providing isotonic IV fluids to rehydrate the patient and help flush out excess calcium [7].
  • Diuretics: Only after adequate rehydration is achieved, and strictly under a specialist’s supervision, a loop diuretic like furosemide might be used to further excrete calcium [8]. Using a diuretic on a dehydrated child before IV fluids are given is highly dangerous.
  • Dietary Adjustments: Doctors in the hospital may temporarily restrict dietary calcium or Vitamin D during a crisis [9]. However, growing children should never be put on restricted diets at home unless explicitly instructed by the treating team.

For children who develop rickets (soft bones), oral phosphate treatment is the most effective way to help bones harden and grow straight [2][10].

Potential Side Effects and Risks

While phosphate is essential for treatment, it can cause some challenges:

  • Stomach Issues: The most common side effect is gastrointestinal discomfort, including diarrhea or abdominal pain [10]. Dividing the daily dose into smaller amounts taken throughout the day can sometimes help, but consult your doctor first.
  • Worsening Deposits: If the balance between phosphate and calcium isn’t monitored closely, supplements could contribute to more calcium deposits in the kidneys [10].
  • Nephrocalcinosis: Because most patients with FRTS2 have some calcium deposits at diagnosis, long-term monitoring with renal ultrasounds is vital to ensure the treatment is protecting the kidneys rather than causing further buildup [2][11].

Treatment for FRTS2 is a long-term commitment that requires a partnership between you and a specialized team [3]. Over time, many children see their symptoms improve significantly as their mineral levels stabilize [3][12].

Common questions in this guide

What is the main treatment for Fanconi renotubular syndrome type 2?
The main treatment is phosphate taken by mouth, which replaces phosphate lost through the kidneys. It aims to restore mineral balance, lower high urine calcium, and support healthy bone growth. The dose is individualized and should not be changed without the treating specialist.
How is the phosphate dose chosen for FRTS2?
The dose depends on a child’s age, the product’s amount of elemental phosphorus, and blood and urine results. Different phosphate salts can contain different amounts of phosphorus, so caregivers should follow the prescription exactly and never recalculate or adjust it on their own.
Should a child with FRTS2 take vitamin D?
Active vitamin D, called calcitriol, is generally avoided because FRTS2 can already cause too much active vitamin D and high calcium. Standard nutritional vitamin D may be prescribed when blood tests show a true deficiency, but any vitamin D or calcium supplement should be directed by the specialist.
How is dangerously high calcium treated in FRTS2?
Severe high blood calcium is a medical emergency and needs hospital assessment. Treatment usually starts with isotonic intravenous fluids, and a loop diuretic such as furosemide may be considered only after adequate rehydration and under specialist supervision. A diuretic must not be given to a dehydrated child without medical direction.
How will doctors monitor long-term FRTS2 treatment?
The team will use regular blood tests for phosphate, calcium, and PTH, or parathyroid hormone, along with urine testing and renal ultrasounds. These checks help confirm that treatment is working and look for calcium deposits in the kidneys, called nephrocalcinosis.
What side effects can oral phosphate cause?
Diarrhea and abdominal discomfort are common possible side effects. Dividing the prescribed daily amount into smaller doses may help some children, but caregivers should ask the treating team before changing how doses are given.
What should caregivers do if a child cannot keep fluids or medicine down?
Ask the specialist for a sick-day plan before an illness occurs. If fluids or oral medicines cannot be kept down, contact the treating team promptly for instructions rather than changing or stopping treatment on your own.

Get notified when new evidence is published on Fanconi renotubular syndrome 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.

    Schlingmann KP, Ruminska J, Kaufmann M, et al.

    Journal of the American Society of Nephrology : JASN 2016; (27(2)):604-14 doi:10.1681/ASN.2014101025.

    PMID: 26047794
  2. 2

    Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series.

    Turan I, Atar M, Eltan M, et al.

    Calcified tissue international 2026; (117(1)):10 doi:10.1007/s00223-025-01462-x.

    PMID: 41543768
  3. 3

    Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c.

    Brunkhorst M, Brunkhorst L, Martens H, et al.

    Kidney international 2025; (107(1)):116-129 doi:10.1016/j.kint.2024.08.035.

    PMID: 39461557
  4. 4

    Antenatal presentation and early postnatal treatment of infantile hypercalcemia type 2.

    Verjans M, Hindryckx A, Rosier K, et al.

    Pediatric nephrology (Berlin, Germany) 2024; (39(10)):2911-2913 doi:10.1007/s00467-024-06403-8.

    PMID: 38753084
  5. 5

    Biallelic mutations in CYP24A1 or SLC34A1 as a cause of infantile idiopathic hypercalcemia (IIH) with vitamin D hypersensitivity: molecular study of 11 historical IIH cases.

    Pronicka E, Ciara E, Halat P, et al.

    Journal of applied genetics 2017; (58(3)):349-353 doi:10.1007/s13353-017-0397-2.

    PMID: 28470390
  6. 6

    Mild Idiopathic Infantile Hypercalcemia-Part 2: A Longitudinal Observational Study.

    Lenherr-Taube N, Furman M, Assor E, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(10)):2938-2948 doi:10.1210/clinem/dgab432.

    PMID: 34139759
  7. 7

    Hypercalcemic Disorders in Children.

    Stokes VJ, Nielsen MF, Hannan FM, Thakker RV

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2017; (32(11)):2157-2170 doi:10.1002/jbmr.3296.

    PMID: 28914984
  8. 8

    Idiopathic infantile hypercalcemia: mutations in SLC34A1 and CYP24A1 in two siblings and fathers.

    Güven A, Konrad M, Schlingmann KP

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(10)):1353-1358.

    PMID: 32866123
  9. 9

    Infantile hypercalcemia with novel compound heterozygous mutation in SLC34A1 encoding renal sodium-phosphate cotransporter 2a: a case report.

    Kang SJ, Lee R, Kim HS

    Annals of pediatric endocrinology & metabolism 2019; (24(1)):64-67 doi:10.6065/apem.2019.24.1.64.

    PMID: 30943683
  10. 10

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  11. 11

    Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations.

    Hureaux M, Molin A, Jay N, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(10)):1723-1729 doi:10.1007/s00467-018-3998-z.

    PMID: 29959532
  12. 12

    Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up.

    Gurevich E, Levi S, Borovitz Y, et al.

    Frontiers in pediatrics 2021; (9()):752312 doi:10.3389/fped.2021.752312.

    PMID: 34858904

This page is for informational purposes only and does not constitute medical advice. Your child’s pediatric kidney specialist should set phosphate, vitamin D, and calcium plans and manage any severe hypercalcemia.